Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer

Chen,Sheng; Wang,Ye; Zhang,Wen‑Long; Dong,Mao‑Sheng; Zhang,Jian‑Hua

doi:10.3892/mmr.2017.6182

Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer

Authors:
- Sheng Chen
- Ye Wang
- Wen‑Long Zhang
- Mao‑Sheng Dong
- Jian‑Hua Zhang
View Affiliations

Affiliations: Department of General Surgery, The General Hospital of the PLA Rocket Force, Beijing 100088, P.R. China, Department of Pathology, China‑Japan Friendship Hospital, Beijing 100029, P.R. China
Published online on: February 8, 2017 https://doi.org/10.3892/mmr.2017.6182
Pages: 1461-1470
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is a type of cancer, which rapidly develops resistance to chemotherapy. Gemcitabine is the treatment used clinically, however, gemcitabine resistance leads to limited efficacy and patient survival rates of only a few months following diagnosis. The aim of the present study was to investigate the mechanisms underlying gemcitabine resistance in pancreatic cancer and to select targeted agents combined with gemcitabine to promote the treatment of pancreatic cancer. Panc‑1 and ASPC‑1 human pancreatic cancer cells (HPCCs) were used to establish the experimental model, and HPCCs were exposed to gemcitabine of serially increased concentrations to generate gemcitabine‑resistant cells (GR‑HPCCs). The anticancer effect of gemcitabine combined with sclareolide was then assessed. Epithelial to mesenchymal transition (EMT), human equilibrative nucleoside transporter 1 (hENT1) and ribonucleoside diphosphate reductase 1 (RRM1) were detected in the HPCCs and GR‑HPCCs, and the mechanisms were investigated. Sclareolide resensitized the GR‑HPCCs to gemcitabine. The expression levels of hENT1 and RRM1 were lower and higher, respectively, in GR‑HPCCs, compared with HPCCs. Sclareolide upregulated hENT1, downregulated RRM1 and inhibited gemcitabine‑induced EMT through the TWIST1/Slug pathway in the GR‑HPCCs. In addition, sclareolide mediated the NOTCH 1 intracellular cytoplasmic domain (NICD)/glioma‑associated oncogene 1 (Gli1) pathway, which triggered TWIST1/Slug‑hENT1/RRM1 signaling and resensitized GR‑HPCCs to gemcitabine. Finally, sclareolide resensitized GR‑HPCCs to gemcitabine through inducing apoptosis; in vivo, the co‑administraion of sclareolide and gemcitabine effectively suppressed tumor growth. Sclareolide may be a novel agent in combination with gemcitabine for the treatment of gemcitabine‑resistant pancreatic cancer, which resensitizes GR‑HPCCs to gemcitabine through mediating NICD and Gli1.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Seicean A, Petrusel L and Seicean R: New targeted therapies in pancreatic cancer. World J Gastroenterol. 21:6127–6145. 2015. View Article : Google Scholar : PubMed/NCBI
3	Massari F, Santoni M, Ciccarese C, Brunelli M, Conti A, Santini D, Montironi R, Cascinu S and Tortora G: Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. Crit Rev Oncol Hematol. 96:81–90. 2015. View Article : Google Scholar : PubMed/NCBI
4	de Sousa Cavalcante L and Monteiro G: Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 741:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
5	Nordh S, Ansari D and Andersson R: hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review. World J Gastroenterol. 20:8482–8490. 2014. View Article : Google Scholar : PubMed/NCBI
6	Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, Baldi GG, Lai R, Rizzo S, et al: Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr Cancer Drug Targets. 11:123–129. 2011. View Article : Google Scholar : PubMed/NCBI
7	Lamba JK: Genetic factors influencing cytarabine therapy. Pharmacogenomics. 10:1657–1674. 2009. View Article : Google Scholar : PubMed/NCBI
8	Jordheim LP and Dumontet C: Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer? Biomark Med. 7:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
9	Jordheim LP, Sève P, Trédan O and Dumontet C: The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 12:693–702. 2011. View Article : Google Scholar : PubMed/NCBI
10	Shah AN, Summy JM, Zhang J, Park SI, Parikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
11	Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ and Choi W: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828. 2009. View Article : Google Scholar : PubMed/NCBI
12	Schaeffer DF, Assi K, Chan K, Buczkowski AK, Chung SW, Scudamore CH, Weiss A, Salh B and Owen DA: Tumor expression of integrin-linked kinase (ILK) correlates with the expression of the E-cadherin repressor snail: An immunohistochemical study in ductal pancreatic adenocarcinoma. Virchows Arch. 456:261–268. 2010. View Article : Google Scholar : PubMed/NCBI
13	Atta-ur-Rahman, Farooq A and Choudhary MI: Microbial transformation of sclareolide. J Nat Prod. 60:1038–1040. 1997. View Article : Google Scholar : PubMed/NCBI
14	González MA, Mancebo-Aracil J, Tangarife-Castaño V, Agudelo-Goméz L, Zapata B, Mesa-Arango A and Betancur-Galvis L: Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide. Eur J Med Chem. 45:4403–4408. 2010. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Jung HY and Yang J: Unraveling the TWIST between EMT and cancer stemness. Cell Stem Cell. 16:1–2. 2015. View Article : Google Scholar : PubMed/NCBI
17	Shih JY and Yang PC: The EMT regulator slug and lung carcinogenesis. Carcinogenesis. 32:1299–1304. 2011. View Article : Google Scholar : PubMed/NCBI
18	Tian Y, Xu Y, Fu Q, Chang M, Wang Y, Shang X, Wan C, Marymont JV and Dong Y: Notch inhibits chondrogenic differentiation of mesenchymal progenitor cells by targeting Twist1. Mol Cell Endocrinol. 403:30–38. 2015. View Article : Google Scholar : PubMed/NCBI
19	Joost S, Almada LL, Rohnalter V, Holz PS, Vrabel AM, Fernandez-Barrena MG, McWilliams RR, Krause M, Fernandez-Zapico ME and Lauth M: GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. Cancer Res. 72:88–99. 2012. View Article : Google Scholar : PubMed/NCBI
20	Gopalakrishnan N, Sivasithamparam ND and Devaraj H: Synergistic association of Notch and NFκB signaling and role of Notch signaling in modulating epithelial to mesenchymal transition in colorectal adenocarcinoma. Biochimie. 107:310–318. 2014. View Article : Google Scholar : PubMed/NCBI
21	Strimpakos AS, Syrigos KN and Saif MW: Pharmacogenomics in pancreatic adenocarcinoma: New data and their clinical implications. JOP. 14:359–362. 2013.PubMed/NCBI
22	Damaraju VL, Scriver T, Mowles D, Kuzma M, Ryan AJ, Cass CE and Sawyer MB: Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity. Clin Cancer Res. 20:176–186. 2014. View Article : Google Scholar : PubMed/NCBI
23	Minami K, Shinsato Y, Yamamoto M, Takahashi H, Zhang S, Nishizawa Y, Tabata S, Ikeda R, Kawahara K, Tsujikawa K, et al: Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. J Pharmacol Sci. 127:319–325. 2015. View Article : Google Scholar : PubMed/NCBI
24	Xie H, Jiang W, Jiang J, Wang Y, Kim R and Liu X and Liu X: Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreaticadenocarcinoma. Cancer. 119:173–181. 2013. View Article : Google Scholar : PubMed/NCBI
25	Montero TD, Racordon D, Bravo L, Owen GI, Bronfman ML and Leisewitz AV: PPARα and PPARγ regulate the nucleoside transporter hENT1. Biochem Biophys Res Commun. 419:405–411. 2012. View Article : Google Scholar : PubMed/NCBI
26	Koo JS and Kim H: Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary. Tumour Biol. 32:893–904. 2011. View Article : Google Scholar : PubMed/NCBI
27	Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, Bulotta A, Neri P, Caraglia M and Tagliaferri P: Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther. 8:648–653. 2009. View Article : Google Scholar : PubMed/NCBI
28	El-Khoueiry AB, Ramanathan RK, Yang DY, Zhang W, Shibata S, Wright JJ, Gandara D and Lenz HJ: A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs. 30:1175–1183. 2012. View Article : Google Scholar : PubMed/NCBI
29	Vena F, Causi EL, Rodriguez-Justo M, Goodstal S, Hagemann T, Hartley JA and Hochhauser D: The MEK1/2 inhibitor Pimasertib enhances gemcitabine efficacy in pancreatic cancer models by altering protein levels of ribonucleotide reductase subunit-1 (RRM1). Clin Cancer Res. 21:5563–5577. 2015. View Article : Google Scholar : PubMed/NCBI
30	Grishina IB: Mini-review: Does notch promote or suppress cancer? New findings and old controversies. Am J Clin Exp Urol. 3:24–27. 2015.PubMed/NCBI
31	Uzdensky AB, Demyanenko SV and Bibov MY: Signal transduction in human cutaneous melanoma and target drugs. Curr Cancer Drug Targets. 13:843–866. 2013. View Article : Google Scholar : PubMed/NCBI
32	Tang SC and Chen YC: Novel therapeutic targets for pancreatic cancer. World J Gastroenterol. 20:10825–10844. 2014. View Article : Google Scholar : PubMed/NCBI
33	Li L and Leung PS: Use of herbal medicines and natural products: An alternative approach to overcoming the apoptotic resistance of pancreatic cancer. Int J Biochem Cell Biol. 53:224–236. 2014. View Article : Google Scholar : PubMed/NCBI
34	Schwanbeck R: The role of epigenetic mechanisms in Notch signaling during development. J Cell Physiol. 230:969–981. 2015. View Article : Google Scholar : PubMed/NCBI
35	Takebe N, Nguyen D and Yang SX: Targeting notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacol Ther. 141:140–149. 2014. View Article : Google Scholar : PubMed/NCBI
36	Gonnissen A, Isebaert S and Haustermans K: Targeting the Hedgehog signaling pathway in cancer: Beyond Smoothened. Oncotarget. 6:13899–13913. 2015. View Article : Google Scholar : PubMed/NCBI
37	Aberger F, Ruiz I and Altaba A: Context-dependent signal integration by the GLI code: The oncogenic load, pathways, modifiers and implications for cancer therapy. Semin Cell Dev Biol. 33:93–104. 2014. View Article : Google Scholar : PubMed/NCBI
38	Merchant JL and Saqui-Salces M: Inhibition of Hedgehog signaling in the gastrointestinal tract: Targeting the cancer microenvironment. Cancer Treat Rev. 40:12–21. 2014. View Article : Google Scholar : PubMed/NCBI
39	Drenkhahn SK, Jackson GA, Slusarz A, Slusarz A, Starkey NJ and Lubahn DB: Inhibition of hedgehog/Gli signaling by botanicals: A review of compounds with potential hedgehog pathway inhibitory activities. Curr Cancer Drug Targets. 13:580–595. 2013. View Article : Google Scholar : PubMed/NCBI
40	Perrot CY, Javelaud D and Mauviel A: Overlapping activities of TGF-β and Hedgehog signaling in cancer: Therapeutic targets for cancer treatment. Pharmacol Ther. 137:183–199. 2013. View Article : Google Scholar : PubMed/NCBI